ANRO Investors: If You Have Suffered Large Losses Contact Robbins LLP for Information About Leading the Alto Neuroscience, Inc. Class Action Lawsuit

Core Viewpoint - A class action has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Allegations and Misleading Information - The Offering Documents related to the IPO were claimed to be negligently prepared, leading to misinformation about ALTO-100's effectiveness in treating major depressive disorder (MDD) [2]. - It was alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, which in turn inflated Alto's business and financial outlook [2]. Group 2: Clinical Trial Results and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial for MDD, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS) [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, representing a 69.99% decline, closing at $4.36 per share on October 23, 2024 [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].